Remyelination News and Research

RSS

Remyelination is a term for the re-generation of the nerve's myelin sheath, damaged in many diseases such as multiple sclerosis (MS) and the leukodystrophies. Remyelination is a subject of active medical research.

Researchers explain how 'viral' agents of neurological diseases ended up in our DNA

What if the missing ‘environmental’ factor in some of our deadliest neurological diseases were really written in our genome?

11 Jul 2019

Innovative compound offers a new therapeutic approach to treat multiple sclerosis

Multiple sclerosis is an autoimmune disease that affects more than 2.3 million people worldwide. This debilitating condition periodically shutters communication between the brain and other parts of the body, resulting in symptoms that range from numbness and tingling in the arms and legs to blindness and paralysis.

22 Feb 2019

Study reveals mechanism behind failed remyelination in MS

Researchers have discovered that in adult stem cells, the activation of a specific transcription factor induces pathological quiescence and that this is deactivated in MS.

18 Dec 2018

Study provides new way to treat multiple sclerosis

Nerve cells stripped of their insulation can no longer carry vital information, leading to the numbness, weakness and vision problems often associated with multiple sclerosis. A new study shows an overlooked source may be able to replace that lost insulation and provide a new way to treat diseases like MS.

27 Nov 2018

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.

8 Oct 2018

Research provides new roadmap for repairing damaged brain cells in multiple sclerosis

Research published today in the journal Nature provides new understanding about how drugs can repair damaged brain cells that cause disability in patients with multiple sclerosis.

26 Jul 2018

Disintegrating brain lesions could predict disease progression in MS patients

For decades, clinicians treating multiple sclerosis have interpreted the appearance of new or expanding brain lesions on magnetic resonance imaging scans as a sign that a patient's disease is getting worse.

5 Jun 2018

Celgene announces regulatory information about investigational compound for relapsing multiple sclerosis

Celgene Corporation today announced that it has received a Refusal to File letter from the United States Food and Drug Administration regarding its New Drug Application for ozanimod in development for the treatment of patients with relapsing forms of multiple sclerosis.

27 Feb 2018

Taurine could boost effectiveness of existing multiple sclerosis therapies

New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies.

8 Dec 2017

Longevity Biotech receives award to evaluate novel drug candidate for MS in preclinical models

Longevity Biotech, Inc. has received an award from the National Multiple Sclerosis Society through Fast Forward, the Society's commercial research funding program, to evaluate LBT-3627 in preclinical models as a potential disease-modifying therapeutic agent.

28 Oct 2017

Myelin sheaths restore impaired nervous system over the long haul

In the central nervous system of humans and all other mammals, a vital insulating sheath composed of lipids and proteins around nerve fibers helps speed the electrical signals or nerve impulses that direct our bodies to walk, talk, breathe, swallow or perform any routine physical act.

24 Oct 2017

Allergy medication restores nervous system function in patients with chronic MS

In a remarkably rapid translation of laboratory research findings into a treatment with the potential to benefit patients, UC San Francisco scientists have successfully completed a Phase II clinical trial showing that an FDA-approved antihistamine restores nervous system function in patients with chronic multiple sclerosis (MS).

11 Oct 2017

Study identifies promising drug candidate for treating demyelinating diseases

Brain functions are maintained by the neural network. Neural network is formed by the connection between the neurite, and this connection is supported by the wrapping of myelin.

26 Aug 2017

Neuronal firing patterns influence proliferation, differentiation of oligodendrocyte precursors

Through their pattern of firing, neurons influence the behavior of the cells that upon maturation will provide insulation of neuronal axons, according to a new study publishing 22 August in the open access journal PLOS Biology by Balint Nagy, Maria Kukley and colleagues at the University of Tübingen, Germany.

23 Aug 2017

Mouse model shows how chronic demyelination may cause seizures in MS patients

Multiple sclerosis is an autoimmune disease of the central nervous system that affects nearly 2.3 million people worldwide.

22 Feb 2017

Researchers identify genetic risk factor for binge eating

Researchers have identified a gene (CYFIP2) associated with binge eating. This finding represents one of the first examples of a genome-wide significant genetic factor to be identified for binge eating in model organisms or humans.

26 Oct 2016

Clinical trial assesses efficacy of experimental treatment in individuals with cervical spinal cord injury

Physicians at Rush University Medical Center became the first in Illinois to inject AST-OPC1 (oligodendrocyte progenitor cells), an experimental treatment, into the damaged cervical spine of a recently paralyzed man as part of a multicenter clinical trial.

14 Sep 2016

Cell therapy product can accelerate brain remyelination in mice

Demyelinating diseases, such as multiple sclerosis and leukodystrophy, are characterized by damage to the protective myelin sheath that surrounds the axons of neurons.

18 Aug 2016

Innovations in pre-clinical MRI: an interview with Priv. Doz. Dr. Dominik von Elverfeldt

To me the most exciting aspect of pre-clinical imaging is its broad range, from very basic science up to applied science. You deal with a range of disciplines including biology, chemistry, physics, biochemistry, biophysics, cell biology and of course medicine, as the aim is the translation of research to humans.

From Bruker BioSpin - NMR, EPR and Imaging 27 Apr 2016

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.

22 Dec 2015